These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 35411433)
21. The value of Liu KY; Goldrich DY; Ninan SJ; Filimonov A; Lam H; Govindaraj S; Iloreta AM Head Neck; 2021 Jun; 43(6):E30-E40. PubMed ID: 33786927 [TBL] [Abstract][Full Text] [Related]
22. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites. Sadowski SM; Neychev V; Millo C; Shih J; Nilubol N; Herscovitch P; Pacak K; Marx SJ; Kebebew E J Clin Oncol; 2016 Feb; 34(6):588-96. PubMed ID: 26712231 [TBL] [Abstract][Full Text] [Related]
23. A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice. Aalbersberg EA; Geluk-Jonker MM; Young-Mylvaganan T; de Wit-van der Veen LJ; Stokkel MPM J Vis Exp; 2019 Apr; (146):. PubMed ID: 31058910 [TBL] [Abstract][Full Text] [Related]
24. Somatostatin receptor imaging with [ Zhao L; Pang Y; Wang Y; Chen J; Zhuang Y; Zhang J; Zhao L; Sun L; Wu H; Chen X; Lin Q; Chen H Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1360-1373. PubMed ID: 34665275 [TBL] [Abstract][Full Text] [Related]
25. A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors. Kayani I; Conry BG; Groves AM; Win T; Dickson J; Caplin M; Bomanji JB J Nucl Med; 2009 Dec; 50(12):1927-32. PubMed ID: 19910422 [TBL] [Abstract][Full Text] [Related]
26. Correlation and Comparison of Somatostatin Receptor Type 2 Immunohistochemical Scoring Systems with 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms. Yu J; Cao F; Zhao X; Xie Q; Lu M; Li J; Yang Z; Sun Y Neuroendocrinology; 2022; 112(4):358-369. PubMed ID: 34077939 [TBL] [Abstract][Full Text] [Related]
27. Use of MRI and Ga-68 DOTATATE for the detection of neuroendocrine liver metastases. Haider M; Jiang BG; Parker JA; Bullock AJ; Goehler A; Tsai LL Abdom Radiol (NY); 2022 Feb; 47(2):586-595. PubMed ID: 34757459 [TBL] [Abstract][Full Text] [Related]
29. Lobular breast cancer bone metastases detected with Barahona Z D; Chong M G; Sola A J Rev Esp Med Nucl Imagen Mol (Engl Ed); 2022; 41 Suppl 1():S44-S45. PubMed ID: 34593349 [No Abstract] [Full Text] [Related]
30. Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors? Has Simsek D; Kuyumcu S; Turkmen C; Sanlı Y; Aykan F; Unal S; Adalet I J Nucl Med; 2014 Nov; 55(11):1811-7. PubMed ID: 25315243 [TBL] [Abstract][Full Text] [Related]
31. Evaluation of (68)Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1. Morgat C; Vélayoudom-Céphise FL; Schwartz P; Guyot M; Gaye D; Vimont D; Schulz J; Mazère J; Nunes ML; Smith D; Hindié E; Fernandez P; Tabarin A Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1258-66. PubMed ID: 26819103 [TBL] [Abstract][Full Text] [Related]
32. Ga-68 DOTA-peptides and F-18 FDG PET/CT in patients with neuroendocrine tumor: A review. Evangelista L; Ravelli I; Bignotto A; Cecchin D; Zucchetta P Clin Imaging; 2020 Nov; 67():113-116. PubMed ID: 32559681 [TBL] [Abstract][Full Text] [Related]
33. Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin. Tran K; Khan S; Taghizadehasl M; Palazzo F; Frilling A; Todd JF; Al-Nahhas A Hell J Nucl Med; 2015; 18(1):19-24. PubMed ID: 25679074 [TBL] [Abstract][Full Text] [Related]
35. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG. Kayani I; Bomanji JB; Groves A; Conway G; Gacinovic S; Win T; Dickson J; Caplin M; Ell PJ Cancer; 2008 Jun; 112(11):2447-55. PubMed ID: 18383518 [TBL] [Abstract][Full Text] [Related]
36. The eye of the beholder: orbital metastases from midgut neuroendocrine tumors, a two institution experience. Das S; Pineda G; Goff L; Sobel R; Berlin J; Fisher G Cancer Imaging; 2018 Dec; 18(1):47. PubMed ID: 30522522 [TBL] [Abstract][Full Text] [Related]
37. Ga-68 DOTATATE PET/CT and F-18 FDG PET/CT in the evaluation of low and intermediate versus high-grade neuroendocrine tumors. You H; Kandathil A; Beg M; De Blanche L; Kazmi S; Subramaniam RM Nucl Med Commun; 2020 Oct; 41(10):1060-1065. PubMed ID: 32732600 [TBL] [Abstract][Full Text] [Related]
38. Theranostic implications of molecular imaging phenotype of well-differentiated pulmonary carcinoid based on Zidan L; Iravani A; Kong G; Akhurst T; Michael M; Hicks RJ Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):204-216. PubMed ID: 32572559 [TBL] [Abstract][Full Text] [Related]
39. Limited role of carbidopa-assisted Imperiale A; Averous G; Helali M; Taieb D; Pessaux P; Goichot B; Addeo P; Bachellier P Ann Nucl Med; 2019 Sep; 33(9):697-707. PubMed ID: 31214959 [TBL] [Abstract][Full Text] [Related]
40. Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach. Werner RA; Weich A; Higuchi T; Schmid JS; Schirbel A; Lassmann M; Wild V; Rudelius M; Kudlich T; Herrmann K; Scheurlen M; Buck AK; Kropf S; Wester HJ; Lapa C Theranostics; 2017; 7(6):1489-1498. PubMed ID: 28529632 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]